Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director · Chief Executive Officer | May 21, 2026 | May 26, 2026 |
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 25, 2026 | June 29, 2026 |
| Oncternal Therapeutics, Inc.GTXI · Entity 89585 | Director | January 02, 2019 | January 03, 2019 |
| Zura Bio LtdZURA · Entity 5413 | Director | May 18, 2023 | May 23, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 190,314 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 100,200 · Balance 190,314 F1: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 26,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 26,000 · Balance 26,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Oncternal Therapeutics, Inc.
Report date January 02, 2019 · Filed January 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,759.211 |
Reported balance
After 2019-01-02 transaction · row 1
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 14,534.884 · Balance 36,759.211 |
Zura Bio Ltd
Report date May 18, 2023 · Filed May 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2033-05-18 | Direct | 7,652 |
Reported balance
After 2023-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-18 · Grant · Acquired 7,652 · Balance 7,652 F1: The option shall vest and become fully exercisable on the earlier of (i) May 18, 2024 or (ii) the date of the next annual meeting of shareholders of Zura Bio Limited. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become fully exercisable on the earlier of (i) May 18, 2024 or (ii) the date of the next annual meeting of shareholders of Zura Bio Limited.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARENA PHARMACEUTICALS INC
Report date March 11, 2022 · Filed March 11, 2022
Section 16 reporting ended · disclosed 2022-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-11 · Other · Disposed 8,150 · Balance 3,067 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Row 2 · 2022-03-11 · Other · Disposed 3,067 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-11 · Disposition to issuer · Disposed 7,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-11 · Disposition to issuer · Disposed 4,167 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-11 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.17 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.50 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.19 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-03-11 · Disposition to issuer · Disposed 7,202 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Aevi Genomic Medicine, LLC
Report date February 03, 2020 · Filed February 05, 2020
Section 16 reporting ended · disclosed 2020-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 1
1 source rowRow 1 · 2020-02-03 · Disposition to issuer · Disposed 2,164,150 · Balance 0 F1: Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2023-09-13 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-03 · Disposition to issuer · Disposed 900,000 · Balance 0 F2: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $6.45 · Expires 2024-04-16 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-03 · Disposition to issuer · Disposed 13,532 · Balance 0 F3: This option, which became exercisable on April 16, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2025-02-18 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2026-04-15 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.91 · Expires 2027-02-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F6: This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-08-11 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F7: The option, which became exercisable beginning on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.51 · Expires 2028-05-14 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-03 · Disposition to issuer · Disposed 300,000 · Balance 0 F9: The option, which became exercisable on May 14, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2028-04-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-02-03 · Disposition to issuer · Disposed 261,000 · Balance 0 F10: The option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Warrant (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2022-10-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-03 · Disposition to issuer · Disposed 13,334 · Balance 0 F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock.
F2: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F3: This option, which became exercisable on April 16, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F6: This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F7: The option, which became exercisable beginning on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void.
F9: The option, which became exercisable on May 14, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F10: The option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:10 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001586785-26-000008 · form4-06292026_080652.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantCommon Stock | 100,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001586785-26-000006 · form4-05262026_040501.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,314 F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionRestricted Stock Units · Derivative | 64,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001586785-26-000004 · form4-03312026_080315.xml · derivative · entry 3 NEIL GARRY ARTHUR · CIK 0001586785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,867 Underlying: Common Stock · 64,866 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F2 · derivative.expiration_date: On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 21,892 | $13.89 | $304,079.88 |
DisclosureSEC source: 0001586785-26-000004 · form4-03312026_080315.xml · nonDerivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,114 Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 64,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001586785-26-000004 · form4-03312026_080315.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:20 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 286,000 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0001586785-26-000002 · form4-03022026_090353.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,000 Underlying: Common Stock · 286,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:10 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016222 · form4-06092025_080657.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:01 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionRestricted Stock Units · Derivative | 64,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000197 · primary_doc.xml · derivative · entry 3 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,733 Underlying: Common Stock · 64,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F2 · derivative.expiration_date: On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:01 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 17,787 | $8.46 | $150,478.02 |
DisclosureSEC source: 0001578563-25-000197 · primary_doc.xml · nonDerivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,140 Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:01 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 64,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-25-000197 · primary_doc.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 22:31 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 411,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001578563-25-000027 · primary_doc.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,000 Underlying: Common Stock · 411,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:00 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantRestricted Stock Units · Derivative | 194,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000363 · primary_doc.xml · derivative · entry 3 NEIL GARRY ARTHUR · CIK 0001586785 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,600 Underlying: Common Stock · 194,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock upon the vesting date. F3 · derivative.exercise_date: The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F3 · derivative.expiration_date: The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:00 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 500,400 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001578563-24-000363 · primary_doc.xml · derivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,400 Underlying: Common Stock · 500,400 shares Expires 2034-08-13 F1 · derivative.exercise_date: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:10 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017155 · form4-06172024_080651.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:10 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010036 · form4-06202023_080604.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:39 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 4,000 | $3.42 | $13,680.00 |
DisclosureSEC source: 0001628280-23-021958 · wk-form4_1686688763.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,220 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:18 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 7,652 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001104659-23-063319 · tm2316481-9_4seq1.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,652 Underlying: Class A Ordinary Shares · 7,652 shares Expires 2033-05-18 F1 · derivative.exercise_date: The option shall vest and become fully exercisable on the earlier of (i) May 18, 2024 or (ii) the date of the next annual meeting of shareholders of Zura Bio Limited. Read SEC document |
| May 15, 2023 Filed May 17, 2023 11:43 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001628280-23-018556 · wk-form4_1684323794.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-05-15 F1 · derivative.exercise_date: The stock option will vest in full on May 15, 2024, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001628280-23-003706 · wf-form4_167649579442477.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 21:22 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 2,083 | $4.42 | $9,206.86 |
DisclosureSEC source: 0001628280-22-031725 · wf-form4_167088011975647.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,220 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 20:03 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001628280-22-026158 · wf-form4_166517298305198.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-10-05 F1 · derivative.exercise_date: The stock option will vest in full on October 5, 2023, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001493152-22-017154 · ownership.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Stock · 27,200 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: One third vests on the first, second and third anniversaries of the date of grant. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 7,202 | Not disclosed Strike: $65.19 | Not disclosed |
DisclosureSEC source: 0001628280-22-005912 · wf-form4_164703375138640.xml · derivative · entry 9 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,202 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $61.31 | Not disclosed |
DisclosureSEC source: 0001628280-22-005912 · wf-form4_164703375138640.xml · derivative · entry 8 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $56.50 | Not disclosed |
DisclosureSEC source: 0001628280-22-005912 · wf-form4_164703375138640.xml · derivative · entry 7 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $49.17 | Not disclosed |
DisclosureSEC source: 0001628280-22-005912 · wf-form4_164703375138640.xml · derivative · entry 6 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $13.60 | Not disclosed |
DisclosureSEC source: 0001628280-22-005912 · wf-form4_164703375138640.xml · derivative · entry 5 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 4,167 | Not disclosed Strike: $14.60 | Not disclosed |
DisclosureSEC source: 0001628280-22-005912 · wf-form4_164703375138640.xml · derivative · entry 4 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,167 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 7,500 | Not disclosed Strike: $14.60 | Not disclosed |
DisclosureSEC source: 0001628280-22-005912 · wf-form4_164703375138640.xml · derivative · entry 3 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 3,067 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-005912 · wf-form4_164703375138640.xml · nonDerivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 8,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-005912 · wf-form4_164703375138640.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067 F1 · kind: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. F1 · price: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:38 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001578563-22-000005 · primary_doc.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2032-03-08 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 22:15 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 4,267 | $1.57 | $6,699.19 |
DisclosureSEC source: 0001879785-21-000037 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,639 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 7,202 | $0.00 Strike: $65.19 | $0.00 |
DisclosureSEC source: 0001628280-21-012275 · wf-form4_162379209349432.xml · derivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,202 Underlying: Common Stock · 7,202 shares Expires 2028-06-11 F2 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 11, 2021 with the final installment vesting upon the earlier of the one-year anniversary of the grant date or the date of the next annual stockholders' meeting, and are exercisable once vested. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 3,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012275 · wf-form4_162379209349432.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,217 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 11, 2022, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:04 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 3,692 | $2.28 | $8,417.76 |
DisclosureSEC source: 0001192482-21-000501 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,372 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:07 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (right to buy) · Derivative | 260,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001192482-21-000118 · edgar.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2031-01-26 F1 · derivative.exercise_date: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:06 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 3,599 | $2.28 | $8,198.52 |
DisclosureSEC source: 0001192482-20-000816 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,680 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:46 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $61.31 | $0.00 |
DisclosureSEC source: 0001209191-20-037106 · doc4.xml · derivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-12 F2 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 12, 2020, and are exercisable once vested. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:46 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 2,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037106 · doc4.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,150 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 12, 2021, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 01:02 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 1,799 | $2.28 | $4,098.12 |
DisclosureSEC source: 0001192482-20-000484 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,081 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 261,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · derivative · entry 10 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 261,000 shares Expires 2028-04-17 F10 · derivative.exercise_date: The option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 300,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · derivative · entry 9 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2028-05-14 F9 · derivative.exercise_date: The option, which became exercisable on May 14, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerWarrant (Right to Purchase) · Derivative | 13,334 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · derivative · entry 8 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,334 shares Expires 2022-10-17 F8 · derivative.exercise_date: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 100,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · derivative · entry 7 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2027-08-11 F7 · derivative.exercise_date: The option, which became exercisable beginning on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 200,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · derivative · entry 6 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2027-02-17 F6 · derivative.exercise_date: This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 200,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · derivative · entry 5 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2026-04-15 F5 · derivative.exercise_date: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 200,000 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · derivative · entry 4 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2025-02-18 F4 · derivative.exercise_date: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 13,532 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · derivative · entry 3 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,532 shares Expires 2024-04-16 F3 · derivative.exercise_date: This option, which became exercisable on April 16, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 900,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · derivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 900,000 shares Expires 2023-09-13 F2 · derivative.exercise_date: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.